March 10, 2020 —  The U.S. Food and Drug Administration (FDA) has cleared the SynCardia Systems 50cc temporary Total Artificial Heart System (50cc TAH-t) as a bridge to transplantation in cardiac transplant eligible patients at risk of imminent death from biventricular failure. With this approval, physicians can now offer the TAH-t to patients with smaller thoracic dimensions including small statured adults, and some pediatric patients.

The European Heart Rhythm Association (EHRA) electrophysiology (EP) annual meeting cancelled due to coronavirus. #COVID19 #coronavirus #2019nCoV

March 10, 2020 — Novel coronavirus (COVID-19) has claimed another large cardiology meeting, the European Heart Rhythm Association (EHRA) has cancelled its 2020 scientific congress scheduled March 29-31 in Vienna, Austria.
Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often present with non-ischemic cardiomyopathy. Both women and men with cardiomyopathies develop heart failure (HF) and are at an increased risk of sudden cardiac death (SCD).
ACC issues document outlining COVID-19 Implications For Patients With Underlying Cardiovascular Conditions. The COVID-19 mortality rate for patients cardiovascular disease is 10.5 percent based of data from Chinese hospitals since the outbreak. COVID-19 fatality rates for patients with comorbidities are higher than the average population, but cardiac patients had the highest death rate. #COVID19 #coronavirus #2019nCoV #SARS‐CoV‐2

March 9, 2020 — The American College of Cardiology (ACC) is offering updates on the clinical impact of novel coronavirus (COVID-19, also called SARS‐CoV‐2) on patients with cardiovascular conditions and other co-morbidities in its COVID-19 Clinical Guidance For the Cardiovascular Care Team document. 

March 9, 2020 — As the novel coronavirus (COVID-19) slowly spreads across the globe, more industry conferences are deciding to cancel their events, many of them offering virtual alternatives. The Society of Interventional Radiology (SIR) is the latest to take this precautionary measure.

ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV

March 9, 2020 — Less than week after the American College of Cardiology (ACC) said it would push ahead with holding its large 2020 annual meeting March 28-30 in Chicago, amid other medical conferences cancelling due to the spread of novel coronavirus (COVID-19), ACC announced today it cancelled the 2020 meeting. 

March 6, 2020 — Researchers at the National Institutes of Health and the University of Wisconsin have demonstrated that using artificial intelligence to analyze computed tomography (CT) scans can produce more accurate risk assessment for major cardiovascular events than current, standard methods such as the


March 5, 2020 – Due to the rapidly evolving novel coronavirus (COVID-19) situation in the U.S. and internationally, the Healthcare Information and Management Systems Society (HIMSS) announced today it is cancelling its five-day 2020 conference, which was slated to begin Monday. The large healthcare conference has more than 40,000 attendees.

March 5, 2020 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical SuperMap, an addition to its AcQMap 3-D imaging and mapping system used to guide electrophysiology (EP) catheter ablation procedures. Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in less than three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation, making it practical to execute an iterative "map, ablate, re-map" approach to diagnosis and therapy.

March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Fully Implantable Left Ventricular Assist System (FILVAS) currently in development. 

The FDA launched the Breakthrough Devices Program in 2018 to help expedite the development and review of submissions for technology that offers significant advantages over existing approved products.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now